

10 December 2013

ASX ANNOUNCEMENT

CONSOLIDATION OF CAPITAL COMPLETED

The Board of Actinogen Limited (ASX: ACW) advises that the consolidation of the Company's securities on a 1:2 basis, approved at the Annual General Meeting held on 29 November 2013, has now been completed.

Details of the Company's shares and options on issue post consolidation are as follows:

- | | |
|---|------------|
| • Fully paid ordinary shares | 51,132,338 |
| • Listed 30/9/2015 options exercisable at \$0.40 each | 9,103,177 |

New holding statements will be despatched to shareholders and option holders on 12 December 2013 advising them of their holding on a post consolidation basis.

In accordance with the timetable for the consolidation, trading on a normal T+3 settlement basis will commence on Tuesday, 17 December 2013 (ASX: ACW and ACWOA).

Settlement of all trades conducted on a deferred settlement basis and first settlement of trades conducted on a T+3 basis will occur on 20 December 2013.

Peter Webse
Company Secretary
Actinogen Limited

About Actinogen Limited Actinogen Limited (ASX: ACW)

Actinogen is dedicated to the discovery and isolation of a group of environmental bacteria known as the Actinomycetes. Actinomycetes have been shown to be able to use a wide range of unusual nutritional resources and often produce bioactive molecules as a by-product that have been proven to be useful to man; including well known commercial examples such as bacterial antibiotics, anti fungal agents, anticancer agents and a variety of other chemicals that are used in the control of physiological and physical processes.

In addition, there are examples of Actinomycetes that can degrade industrial wastes such as oils, tar, domestic and industrial waste, and the rehabilitation of oil spills. Actinogen has proven high-level expertise in the discovery and isolation of Actinomycetes from WA soils and in the detection of bioactive molecules they produce. During 2011, Actinogen began a bio-ethanol research program, which has had very encouraging results and to date is a focal project for the company. The Company's strategy is to collaborate with groups nationally and internationally who are active in the development of technology that is synergistic with or that could utilise the Company's current Actinomycetes research projects and exclusive intellectual property.